Orgenesis (FRA:45O0) Treasury Stock : €-1.14 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Orgenesis Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Orgenesis's treasury stock for the quarter that ended in Sep. 2024 was €-1.14 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Orgenesis Treasury Stock Historical Data

The historical data trend for Orgenesis's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Treasury Stock Chart

Orgenesis Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Dec19

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Get a 7-Day Free Trial

-0.21

-1.12

-1.20

-1.16

Orgenesis Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Treasury Stock	Get a 7-Day Free Trial															-1.19	-1.16	-1.17	-1.18	-1.14

Orgenesis Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Orgenesis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (FRA:45O0) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

ORGS:USA 45O0:Germany

Address

20271 Goldenrod Lane, Germantown, MD, USA, 20876

Website

https://www.orgenesis.com

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.

Orgenesis Headlines

No Headlines